ZLDAF (Zelira Therapeutics) Inventories, Finished Goods: $0.01 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zelira Therapeutics Inventories, Finished Goods?

Zelira Therapeutics ZLDAF Inventories, Finished Goods is $0.01 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

Zelira Therapeutics's quarterly finished goods increased from Jun. 2024 ($0.03 Mil) to Dec. 2024 ($0.03 Mil) but then declined from Dec. 2024 ($0.03 Mil) to Jun. 2025 ($0.01 Mil).

Zelira Therapeutics's annual finished goods declined from Jun. 2023 ($0.25 Mil) to Jun. 2024 ($0.03 Mil) and declined from Jun. 2024 ($0.03 Mil) to Jun. 2025 ($0.01 Mil).

Zelira Therapeutics Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Inventories, Finished Goods Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.52 0.25 0.03 0.01

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.14 0.03 0.03 0.01

Zelira Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.01 Mil mean?
Zelira Therapeutics (ZLDAF) has a Inventories, Finished Goods of $0.01 Mil as of Jun. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Inventories, Finished Goods too high?
Zelira Therapeutics' current Inventories, Finished Goods is $0.01 Mil.
How does Zelira Therapeutics' Inventories, Finished Goods compare to CLDI and CRIS?
Zelira Therapeutics' Inventories, Finished Goods of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Inventories, Finished Goods is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ZLDAF) has a current Inventories, Finished Goods of $0.01 Mil. The current Inventories, Finished Goods is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current Inventories, Finished Goods is $0.01 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is an Australian biotechnology company that develops and commercializes cannabinoid-based medicines for a range of medical conditions. Its product portfolio includes proprietary formulations such as HOPE, Zenivol and Dalirex, targeting areas including insomnia, chronic pain, autism, eczema and other neurological and inflammatory conditions. The company advances these assets through clinical and preclinical research programs, and also sells medicinal cannabis products in Australia through prescription channels. Zelira operates across two geographic segments, Australia and the United States, where it has pursued partnerships and licensing arrangements to commercialize its formulations in the US market. Revenue is generated primarily from product sales of its medicinal cannabis formulations and from licensing and collaboration agreements with partners. The company is headquartered in Perth, Western Australia, and its shares are listed on the Australian Securities Exchange.